Baader Bank Aktiengesellschaft Makes New $341,000 Investment in Novo Nordisk A/S (NYSE:NVO)

Baader Bank Aktiengesellschaft purchased a new stake in shares of Novo Nordisk A/S (NYSE:NVO) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 4,076 shares of the company’s stock, valued at approximately $341,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. International Assets Investment Management LLC lifted its holdings in Novo Nordisk A/S by 10,608.4% during the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after purchasing an additional 1,796,635 shares during the last quarter. Mediolanum International Funds Ltd bought a new stake in shares of Novo Nordisk A/S in the third quarter valued at approximately $98,765,000. Wellington Management Group LLP bought a new position in Novo Nordisk A/S in the 3rd quarter worth approximately $42,017,000. World Investment Advisors LLC grew its stake in Novo Nordisk A/S by 2,655.9% in the 3rd quarter. World Investment Advisors LLC now owns 280,409 shares of the company’s stock valued at $33,388,000 after buying an additional 270,234 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Novo Nordisk A/S by 71.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 475,490 shares of the company’s stock valued at $57,413,000 after acquiring an additional 198,891 shares during the period. Institutional investors own 11.54% of the company’s stock.

Analysts Set New Price Targets

NVO has been the subject of a number of analyst reports. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. BMO Capital Markets reduced their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Finally, BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Trading Up 1.5 %

Shares of Novo Nordisk A/S stock opened at $85.33 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a 1 year low of $78.17 and a 1 year high of $148.15. The firm has a market cap of $382.91 billion, a PE ratio of 27.61, a PEG ratio of 0.90 and a beta of 0.45. The company has a 50 day simple moving average of $94.32 and a two-hundred day simple moving average of $113.82.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.